anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition exhibiting inhibitory effect against rising in blood glucose level or lowering effect for blood glucose level when put to transtracheal administration by dissolving or dispersing an extract concentrate of Logerstroemia Speciosa Linn. Leaves in an aqueous medium. SOLUTION: This liquid composition is obtained by dissolving or dispersing (A) an active ingredient, a concentrate of hot water extract or alcohol (pref. lower alcohol) extract of Logerstroemia Speciosa Linn. Leaves in (B) an aqueous medium; wherein the concentrate contains corosolic acid whose content is pref. 0.5-3 wt.% in this composition. The other objective heat transpirator is made up of a container 1 holding the above composition and a porous form 3 having a length ranging from the bottom of the container 1 to a point above the container 1 and intended for sucking this composition and transpiring the active ingredient by heating on the upper end; wherein the heating is made using pref. an electrothermal ceramic heater.
BACKGROUND: Over the years, different techniques have been developed to reduce the number of incisions and scars in subnasal lip lifting and to increase the amount of lifting. The aim of this study was to present a new technique to hide the scars at the nasal base in subnasal lip lifting procedures and to review the literature.
METHODS: The file of patients who underwent subnasal lip lifting between January 2019 and January 2021 were examined. In all patients, the nasal sill flap that was designed was elevated, and the nasal sill flap that was prepared was adapted to its new location when the excision had been completed. Two different plastic surgeons evaluated the patients in the postoperative 12-month follow-ups. The scars were evaluated for vascularity, pigmentation, elasticity, thickness, and height.
RESULTS: The study included 26 patients. While 21 patients had no histories of lip lifting, five patients had had previous lip lifting history. The mean operation time was 37.11 minutes. Patients' skin types were determined as Type 3 in 18 patients and Type 4 in eight patients according to the Fitzpatrick classification. The mean follow-up period of the patients was 13.11 months. At the end of the 12-month period, the mean scar score of the patients was calculated as 11.15. The mean scar score of primary cases was 11.14, and the mean scar score of secondary cases was 11.20 (p = 0.983). There was no statistically significant difference in terms of complications among smokers (p = 0.356). The mean scar score was calculated as 12.17 in patients who had Type 3 skin and 8.88 in patients with Type 4 skin (p = 0.075).
CONCLUSIONS: This technique is beneficial for patients because the scars are discrete and easier for patients to accept.
The current invention is an ophthalmic composition that combines multiple agents necessary to perform a routine eye examination. Preferably, the composition is a mixture of a topical local anesthetic, a pupillary dilating agent, and a dye, all in solution. The composition may also include a preservative, a wetting agent, a diluting agent, and/or a buffer. The preferred composition provides a means to: 1) anesthetize the cornea to allow for pain relief, manipulation and the measurement of intraocular pressure, 2) dye the cornea and conjunctiva to allow for the detection of pathology and for the measurement of intraocular pressure, and 3) dilate the pupil to allow for examination of the optic nerve, macula, retina, retinal vasculature, and peripheral fundus. In addition, the invention includes a method of using the inventive composition and a method of using currently available compositions that allow for a more rapid eye examination by eliminating or reducing a waiting period that follows the administration of dilating agents according to the present state of the art. Moreover, the inventive composition may be used pre-operatively before ophthalmic surgery, thereby conferring many of the same advantages as described above.
PURPOSE:To obtain soft capsule not to collapse by water transfer, by packing a core solution comprising a hydrophilic material having a given water activity value into a specific coating film made of gelatin. CONSTITUTION:A core solution comprising a hydrophilic material having 0.55-0.80 water activity value is packed into a coating film made of gelatin which is mixed with a humectant to provide a higher water activity value than that of the core solution to give soft capsule. When the water activity value of the core solution becomes higher than 0.80, since the water activity value of the coating film is always kept >=the water activity value of the core solution, the water activity value of the coating film becomes higher than 0.80. Consequently, the water content of the coating film becomes high, unfavorably softening and adhesion of capsule and oxidation of content occur. In order to adjust the water activity value of the core solution to <0.55, a large amount of addition of a substance having lowering action on water activity to the core solution is required. Consequently, the core solution becomes viscous and unfavorably workability of production process becomes bad.
PURPOSE:To obtain the titled product useful for internal use, edible use, external embrocation, etc. as medicines, cosmetics, antioxidants, for food without using a surfactant, by entrapping oryzanol in cyclodextrin in a mixed solvent of acetone and water. CONSTITUTION:The aimed product is obtained by any one of the following methods; (A) Oryzanol solution in acetone, e.g. 0.1% solution, is mixed with an aqueous solution of cyclodextrin, e.g. a 4% solution, and a small amount of aqueous ammonia is added to form a uniform mixture solution under stirring. The resultant mixture solution is directly concentrated to drynss under reduced pressure. (B) After addition of the above-mentioned aqueous ammonia, the mixture solution is refluxed at 70-80 deg.C for 5-6hr, allowed to stand overnight and then concentrated to dryness under reduced pressure. (C) The above-mentioned two solutions are mixed, and stirred for about 15-20hr without addition of the aqueous ammonia. The resultant mixture solution is then concentrated to dryness under reduced pressure, washed with acetone, air-dried and then pulverized to give a powdery material.
NEW MATERIAL:A 4-amino-2,3-cycloalkenopyridine expressed by formula I [A is alkylene expressed by formula (n is 3-5) which can be bonded to adjacent two carbons of adjacent pyridine to form one cycloalkeno; when A forms cycloalkeno, Y is H, halogen, 1-4C alkyl, etc. and Z is H, OH, halogen, pyrrolidyl, etc.] and 4-aminoquinoline derivative or salt thereof. EXAMPLE:4-Amino-6-chloro-2,3-cyclopentenopyridine. USE:A medicine. Cerebral functional disorder improver and remedy for heart failure, capable of exhibiting acetylcholinesterase inhibiting action, 5- lipoxygenase inhibiting action, etc. PREPARATION:A pyridine derivative expressed by formula III (D is H or lower alkyl, etc.) is reacted with phosphorus halide and then reacted with a compound expressed by the formula Z-H (Z' is not H) to provide the aminopyridine expressed by formula I (Y is halogen, lower alkyl, etc.).
SPC25 is associated with unfavorable outcomes in various cancers, but its role in prostate cancer (PRAD) is unclear. More research is needed on glycolysis and ferroptosis targets in PRAD. Bioinformatics tools were used to analyze SPC25 expression disparities. Gene set enrichment analysis (GSEA) identified pathways enriched by SPC25 and its correlation with glycolytic proteins. SPC25 mRNA transcriptional activity was analyzed by quantitative polymerase chain reaction (qPCR), while protein levels of SPC25, glycolytic markers, and ferroptosis markers were assessed using Western blot. CCK-8 was used to evaluate the effects of SPC25 on cell survival. Ferroptosis levels were measured by flow cytometry and assays for Fe2+ and malondialdehyde (MDA) content. Glycolytic capacity was assessed using glucose uptake assays, lactate tests, and a Seahorse XF analyzer. In PRAD tissues and cells, SPC25 was notably upregulated and correlated with adverse outcomes. It enhanced cancer cell vitality. GSEA showed SPC25's strong association with ferroptosis and glycolytic pathways, while Pearson correlation analysis indicated a positive relationship between SPC25 and glycolytic proteins. Overexpression of SPC25 in cell lines noticeably curbed the accumulation of lipid reactive oxygen species, MDA formation, and Fe2+ content, while it augmented the protein expression of ferroptosis markers. SPC25 stimulated an increase in cellular extracellular acidification rate, glucose uptake, and lactate secretion, while it dampened oxygen consumption rate, and this effect could be counteracted by 2-deoxy-d-glucose (2-DG). Conversely, 2-DG mitigated the ferroptosis indicators that were diminished by SPC25 downregulation, including the reduction of ferroptosis marker protein expression. By upregulating glycolysis in PRAD cells, SPC25 suppresses the occurrence of ferroptosis.
Lateral epicondylitis or tennis elbow is a often-encountered disorder of elbow which is characterized by tenderness and pain over lateral epicondylitis of humerus and grip weakness. The annual incidence of lateral epicondylitis has been reported to be %1-3 in general population. Lateral epicondylitis is commonly associated with repetitive overuse of wrist, activities including strong grip which in turn cause microtears and degenerative changes over the common origin of wrist and finger extensors on lateral epicondyle. New researches have shown that the underlying mechanism is degenerative rather than inflammatory. It has been proposed that the cause of pain may be mechanical discontinuity of collagen fibers or biochemical irritation that results from damaged tendon tissue that activates nociceptors. It has been suggested that eccentric loading has been shown to assist with tendon rehabilitation by improving collagen alignment and stimulating collagen cross-linkage formation, both of which can improve tensile strength.

Kinesio taping (KT) which is a new application of adhesive taping was designed by Kenzo Kase to avoid unwanted effects of conventional taping such as restricting range of motion (ROM) and limiting functional activities. The recommended tape application methods are outlined in 'Clinical Therapeutic Applications of the Kinesio Taping Method' 8. Elastic therapeutic tape has been designed to allow for a longitudinal stretch of up to 140% of its resting length and has been designed to approximate the elastic qualities of the human skin. In particular, the application of the tape over stretched muscle to create convolutions in the skin has been hypothesized to reduce pressure in the mechanoreceptors below the dermis, thereby decreasing nociceptive stimuli. Another mechanism which is claimed by the proponent of the tape is that convolutions are raised ridges of the tape and the skin that are thought to decompress underlying structures and allow for enhanced circulation by increased subcutaneous space. In the last few years, the use of KT has become increasingly popular in rehabilitation programs as an adjunct in the treatment. However, scientific evidence about its effect is insufficient.

The aim of this study is to compare the effects of kinesiology taping with exercise, sham taping with exercise and exercise alone for lateral epicondylitis.
The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1 P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.
BACKGROUND: Chronic hepatitis B (CHB) is endemic in the Aboriginal and Torres Strait Islander population of Australia's Northern Territory. Progression to liver disease can be prevented if holistic care is provided. Low health literacy amongst health professionals is a known barrier to caring for people living with CHB. We co-designed and delivered a culturally safe "Managing hepatitis B" training course for the Aboriginal health workforce. Here, we present an evaluation of the course.
OBJECTIVES: 1. To improve course participants CHB-related knowledge, attitudes, and clinical practice. 2. To evaluate the "Managing hepatitis B" training course. 3. To enable participants to have the skills and confidence to be part of the care team.
METHODS: We used participatory action research and culturally safe principles. We used purpose-built quantitative and qualitative evaluation tools to evaluate our "Managing hepatitis B" training course. We integrated the two forms of data, deductively analysing codes, grouped into categories, and assessed pedagogical outcomes against Kirkpatrick's training evaluation framework.
RESULTS: Eight courses were delivered between 2019 and 2023, with 130 participants from 32 communities. Pre- and post-course questionnaires demonstrated statistically significant improvements in all domains, p<0.001 on 93 matched pairs. Thematic network analysis demonstrated high levels of course acceptability and significant knowledge acquisition. Other themes identified include cultural safety, shame, previous misinformation, and misconceptions about transmission. Observations demonstrate improvements in post-course engagement, a deep understanding of CHB as well as increased participation in clinical care teams.
CONCLUSIONS: The "Managing hepatitis B" training course led to a sustained improvement in the knowledge and attitudes of the Aboriginal health workforce, resulting in improved care and treatment uptake for people living with CHB. Important non-clinical outcomes included strengthening teaching and leadership skills, and empowerment.
Intestinal microbiome contains several times of functional genes compared to the host and mediates the generation of multiple metabolic products, and therefore it is called "second genome" for host. Crustaceans rank second among the largest subphylum of aquaculture animals that are considered potentially satisfy global substantial food and nutrition security, among which the Pacific white shrimp (Litopenaeus vannamei) ranks the first in the production. Currently, increasing evidences show that outbreaks of some most devastating diseases in shrimp, including white feces syndrome (WFS) and acute hepatopancreatic necrosis disease (AHPND), are related to intestinal microbiota dysbiosis. Importantly, the intestine microbial composition can be altered by environmental stress, diet, and age. In this review, we overview the progress of intestinal microbiota dysbiosis and WFS or ANPHD in shrimp, and how the microbial composition is altered by external factors. Hence, developing suitable microbial micro-ecological prevention and control strategy to maintain intestinal balance may be a feasible solution to reduce the risk of disease outbreaks. Moreover, we highlight that defining the "healthy intestine microbiota" and evaluating the causality of intestinal microbiota dysbiosis and diseases following the logic of "Microecological Koch's postulates" should be the key goal in future shrimp intestinal field, which help to guide disease diagnosis and prevent disease outbreaks in shrimp farming. KEY POINTS: • Intestinal microbiota dysbiosis is relevant to multiple shrimp diseases. • Microecological Koch's postulates help to evaluate the causality of shrimp diseases.
Alumunium usage and toxicity has been a global concern especially an increased use of nanoparticulated aluminum (Al-NPs) products from the environment and the workplace. Al degrades in to nanoparticulate form in the environment due to the routine process of bioremediation in human body. Al-NPs toxicity plays key role in the pathophysiology of neurodegeneration which is characterised by the development of neurofibrillary tangles and neuritic plaques which correlates to the Alzheimer's disease. This study evaluated the Al-NPs induced neurodegeneration and causative behavioral alterations due to oxidative stress, inflammation, DNA damage, β-amyloid aggregation, and histopathological changes in mice. Furthermore, the preventive effect of naringenin (NAR) as a potent neuroprotective flavonoid against Al-NPs induced neurodegeneration was assessed. Al-NPs were synthesized and examined using FTIR, XRD, TEM, and particle size analyzer. Mice were orally administered with Al-NPs (6 mg/kg b.w.) followed by NAR treatment (10 mg/kg b.w. per day) for 66 days. The spatial working memory was determined by novel object recognition, T-maze, Y-maze, and Morris Water Maze tests. We measured nitric oxide, advanced oxidation of protein products, protein carbonylation, lipid peroxidation, superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase, reduced glutathione, oxidised glutathione, and acetylcholine esterase, as well as cytokines analysis, immunohistochemistry, and DNA damage. Al-NPs significantly reduced the learning memory power, increased oxidative stress, reduced antioxidant enzymatic activity, increased DNA damage, altered the levels of cytokines, and increased β-amyloid aggregation in the cortex and hippocampus regions of the mice brain. These neurobehavioral impairments, neuronal oxidative stress, and histopathological alterations were significantly attenuated by NAR supplementation. In conclusion, Al-NPs may be potent neurotoxic upon exposure and that NAR could serve as a potential preventive measure in the treatment and management of neuronal degeneration.
Patients undergo chest CT every 3 months for years 1-2, and every 6 months years 3-5. Patients with a suspicious or new nodule may undergo a biopsy on study.
BACKGROUND: Histone deacetylase 4 (HDAC4) and histone deacetylase 5 (HDAC5) are two isoforms of class IIa HDACs, and LMK235 is an HDAC inhibitor with higher selectivity for HDAC4/5. This study aimed to explore the expression and subcellular localization of HDAC4/5 and determine the mechanisms underlying the impact of LMK235 on ventricular remodelling post-MI.
METHODS: The MI model was established by left anterior descending branch (LAD) ligation, and LMK235 or vehicle was intraperitoneally injected daily for 21 days. Cardiac function was determined by echocardiography. Inflammation was evaluated by HE staining and measuring inflammatory cytokine expression, and fibrosis was evaluated by Masson staining and measuring fibrotic biomarker expression.
RESULTS: We found that LMK235 ameliorated cardiac dysfunction post-MI by suppressing inflammation and fibrosis, and LMK235 inhibited upregulation of lysine-specific demethylase 1 (LSD1) expression post-MI. In macrophages, LMK235 attenuated lipopolysaccharide (LPS) - induced inflammatory cytokine expression and inhibited LSD1 expression, while overexpression of LSD1 abrogated the anti-inflammatory effect of LMK235. In cardiac fibroblasts, LMK235 attenuated transforming growth factor-β1 (TGF-β1) - induced fibrotic biomarker expression and inhibited LSD1 expression, while overexpression of LSD1 abrogated the antifibrotic effect of LMK235.
CONCLUSION: LMK235 attenuates chronic inflammation and fibrosis post-MI, leading to improved cardiac function. The anti-inflammatory effect of LMK235 may result from inhibition of the LSD1-NF-κB pathway in macrophages. The antifibrotic effect of LMK235 may result from inhibition of the LSD1-Smad2/3 pathway in cardiac fibroblasts.
Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to 1H-quinazoline-2,4-diones of formula and to their pharmaceutically acceptable salts where R1 and R2 have the values specified in cl. 1 of the patent claim. The specified compounds exhibit antagonistic activity with respect to the AMPA receptor. ^ EFFECT: reception of a pharmaceutical composition for preparing a preparation used for treating a condition mediated by the AMPA receptor and first of all for treating epilepsy or schizophrenia. ^ 8 cl, 81 ex
Pediatric patients with PKU, ages 1 month to 16 years, have been treated with KUVAN in clinical trials [see Clinical Studies (14)].

The efficacy and safety of KUVAN have not been established in neonates. The safety of KUVAN has been established in children younger than 4 years in trials of 6 months duration and in children 4 years and older in trials of up to 3 years in length [see Adverse Reactions (6.1)].

In children aged 1 month and older, the efficacy of KUVAN has been demonstrated in trials of 6 weeks or less in duration [see Clinical Studies (14)]. 

In a multicenter, open-label, single arm study, 57 patients aged 1 month to 6 years who were defined as KUVAN responders after 4 weeks of KUVAN treatment and Phe dietary restriction were treated for 6 months with KUVAN at 20 mg/kg per day. The effectiveness of KUVAN alone on reduction of blood Phe levels beyond 4 weeks could not be determined due to concurrent changes in dietary Phe intake during the study. Mean (±SD) blood Phe values over time for patients aged 1 month to <2 years and 2 to <7 years are shown in Figure 1.
PURPOSE:To provide an external agent for skin, having excellent storage stability and containing a drying oil or semidrying oil, and an oil component selected from branched saturated fatty acid ester, branched saturated aliphatic alcohol ester, straight-chain monoene fatty acid ester, silicone oil, etc. CONSTITUTION:The objective external agent for skin contains (A) a drying oil (e.g. linseed oil, perilla oil, soybean oil, etc.) or a semidrying oil (e.g. rapeseed oil, sesame oil, etc.) and (B) an oil component selected from an ester of a branched saturated fatty acid or a straight-chain monoene fatty acid and a polyhydric alcohol, an ester of a branched saturated aliphatic alcohol and a saturated aliphatic dibasic acid, an ester of a straight-chain monoene fatty acid and straight-chain monoene aliphatic acid, macadamia nut oil, camellia oil, and silicone oil of formula I or II (m is 0-650; R1-R8 are H, CH3 or phenyl; n is 3-7; R9 and R10 are H or CH3), etc. The weight ratio of A to B is 1 to <=2.5. The agent exhibits high storage stability while keeping the merits of the (semi)drying oil.